drugset / Trial / NCT04021238

Contrast-Enhanced Ultrasound for Kidney Cancer Subtyping and Staging

NCT04021238

Phase 2 Completed 25 enrolled UNC Lineberger Comprehensive Cancer Center
NaSingle-groupOpen-labelDiagnostic

Summary

The purpose of this study is to determine if contrast-enhanced ultrasound can detect abnormal features of kidney lesions in patients with suspected kidney cancer with the same accuracy as conventional ultrasound and contrast-enhanced magnetic resonance imaging (MRI)

Timeline

Start
2020-10-07
Primary completion
2022-08-05
Completion
2022-08-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Definity Diagnostic / imaging agent Intravenous
Subject Lumason Diagnostic / imaging agent Intravenous

Indications